The chief function of the Neuropathology Core (NC) is to provide state of the art diagnostic services, to set up and maintain a collection of optimally prepared brain samples, and to supply samples for cutting edge research to investigators of the Center, affiliated Centers, and to outside neuroscientists conducting research into neurodegenerative diseases. Because humans are the only known species to naturally develop Alzheimer disease (AD) or related illnesses, the availability of carefully prepared postmortem samples is essenfial despite the existence of valuable transgenic animal models. Thus, human fissue-dependent studies require that the diagnostic categorization of samples of interest is as accurate as possible. This tissue must be made available quickly following the receipt of a request to enhance laboratory efficiency and productivities. Therefore, the specific aims of NC are: 1. To establish an accurate diagnosis on all brains obtained for the Center including clinico-pathological interpretations of the findings, which are recorded within two standardized reports;a) a text-based for clinicians and medical files, and b) a quantification-based report. The quantificafion-based report provides data to the Clinical Care / Data Management, and to the National Alzheimer's Coordinafing Committee (NACC) in compliance with National Institute on Aging (NIA) requirements. Furthermore, it is used for identifying the samples in storage with variables matching those specified by requestors;2. To obtain brain samples for tissue-dependent fresh frozen studies with or without requirement of cellular morphology preservation, which are ready for immediate disbursement once categorized;and formalin fixed samples;3. To organize the collecfion of samples, maintain it safely, and select among the samples in storage the ones that best match the requirement of a specific study with subsequent distribution within five working days from the time the receipt of the request;4. To teach clinicians, trainees, and neuroscientists the neuropathology of the demenfias, and to assist in correlating findings made in transgenic animal models with those usually occurring in the human brains;and 5. To cooperate with other Centers including the Nafional Institute of Neurological Disorders and Stroke (NINDS) supported Udall Center.
Defining the changes underlying dementias is prerequisite for knowing how to prevent them. Therefore, brains of individuals who died at different stage of the dementia, and recording the type, extend, and distribution of the changes must be achieved to optimize the specificity of samples defined for basic research including tissue-dependent investigations aiming at disclosing the causes of dementias.
|Vardarajan, Badri N; Zhang, Yalun; Lee, Joseph H et al. (2015) Coding mutations in SORL1 and Alzheimer disease. Ann Neurol 77:215-27|
|Mecozzi, Vincent J; Berman, Diego E; Simoes, Sabrina et al. (2014) Pharmacological chaperones stabilize retromer to limit APP processing. Nat Chem Biol 10:443-9|
|Pan, Jie J; Lee, Michelle; Honig, Lawrence S et al. (2014) Alzheimer's-related changes in non-demented essential tremor patients vs. controls: links between tau and tremor? Parkinsonism Relat Disord 20:655-8|
|Baleriola, Jimena; Walker, Chandler A; Jean, Ying Y et al. (2014) Axonally synthesized ATF4 transmits a neurodegenerative signal across brain regions. Cell 158:1159-72|
|Pelton, Gregory H; Andrews, Howard; Roose, Steven P et al. (2014) Donepezil treatment of older adults with cognitive impairment and depression (DOTCODE study): clinical rationale and design. Contemp Clin Trials 37:200-8|
|Sproul, Andrew A; Jacob, Samson; Pre, Deborah et al. (2014) Characterization and molecular profiling of PSEN1 familial Alzheimer's disease iPSC-derived neural progenitors. PLoS One 9:e84547|
|Khan, Usman A; Liu, Li; Provenzano, Frank A et al. (2014) Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer's disease. Nat Neurosci 17:304-11|
|Salloway, Stephen; Sperling, Reisa; Fox, Nick C et al. (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 370:322-33|
|Choi, Ben Jiwon; Imlach, Wendy L; Jiao, Wei et al. (2014) Miniature neurotransmission regulates Drosophila synaptic structural maturation. Neuron 82:618-34|
|Salm, Melissa; Abbate, Kristopher; Appelbaum, Paul et al. (2014) Use of genetic tests among neurologists and psychiatrists: knowledge, attitudes, behaviors, and needs for training. J Genet Couns 23:156-63|
Showing the most recent 10 out of 350 publications